Product Images Desvenlafaxine

The text provides information on the change due to PK geometric mean ratio (90% CI) of CYP3A4 inhibitors such as Ketoconazole. The table shows the change relative to reference with values for Ketoconazole listed as 1.08 (1.00-1.17) and 143 (1.38-1.49). However, there is not enough context to determine the exact meaning of these values.*

This appears to be a graphical representation of the estimated proportion of patients with relapse over time (in days from randomization) for those taking Desvenlafaxine Extended-release Tablets (50 mg) and those taking a placebo. The relapse rate for those taking the medication appears to be lower than for those taking the placebo.*

This text appears to be a graph showing the estimated proportion of patients with relapse over time for a treatment called "Desvenlafaxine Extended-release Tablets" compared to placebo. The x-axis shows the time to relapse in days from randomization and the y-axis shows the estimated proportion of patients with relapse in percentages. The graph indicates that after about 50 days from randomization, approximately 50% of patients taking the Desvenlafaxine Extended-release Tablets experienced relapse, while the proportion of patients experiencing relapse while taking placebo was not available as the graph ends at 0%.*

Desvenlafaxine is an extended-release tablet that contains 72.42 mg of desvenlafaxine succinate, which is equivalent to 50 mg desvenlafaxine. The tablet should be swallowed whole and should not be crushed, cut, chewed or dissolved. It is stored at 20°C to 25°C (68°F to 77°F) and dispensed as a unit by a pharmacist. The package inserts contain complete information on usage. This unit of use contains 14 tablets, and it is distributed by Zydus Pharmaceuticals (USA) Inc. in Pennington, NJ.*

Desvenlafaxine is a medication available in extended-release tablets that contain 144.84mg of desvenlafaxine succinate, equivalent to 100mg desvenlafaxine. The usual dosage information is available in the package insert. This medication should be swallowed whole and not crushed, cut, chewed, or dissolved. It should be stored at temperatures between 20-25°C. The package is not intended to be divided and should be kept out of the reach of children. A guide is provided separately to each patient. This medication is manufactured by Cadila Healthcare Ltd in India and distributed by Zydus Pharmaceuticals (USA) Inc. in Pennington, NJ 08534.*